Adagio Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Adagio Therapeutics's estimated annual revenue is currently $17.5M per year.
- Adagio Therapeutics's estimated revenue per employee is $192,473
- Adagio Therapeutics's total funding is $466M.
Employee Data
- Adagio Therapeutics has 91 Employees.
- Adagio Therapeutics grew their employee count by -9% last year.
Adagio Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $4.2M | 27 | 35% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $1.4M | 9 | 29% | N/A | N/A |
#6 | $235M | 255 | -31% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.3M | 34 | 0% | N/A | N/A |
#10 | $1.9M | 12 | -8% | N/A | N/A |
What Is Adagio Therapeutics?
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program is expected to enter the clinic by the end of 2020.
keywords:N/A$466M
Total Funding
91
Number of Employees
$17.5M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Adagio Therapeutics News
Adagio Therapeutics Inc (ADGI) is higher by 2.23% Tuesday In Premarket Trading. Tuesday, April 19, 2022 07:09 AM | InvestorsObserver Analysts.
Adagio Therapeutics Inc (ADGI) is down -0.84%% today. Overall Score - 40. ADGI has an Overall Score of 40. Find out what this means to you and...
WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company...
Adagio Therapeutics, a Waltham startup advancing COVID-19 antibody treatments, is going public Friday just over one year after it was founded. The company raised nearly $310 million by selling 18,200,000 shares for $17 each, in the middle of its expected range, and it will trade on the Nasdaq G ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $24.6M | 91 | 12% | N/A |
#2 | $9.3M | 91 | 2% | N/A |
#3 | $30.8M | 94 | 29% | N/A |
#4 | $16.1M | 95 | -10% | $233M |
#5 | $9.6M | 96 | -5% | N/A |